October 2026 Global Biopharma Clinical Highlights

In October 2026, a number of notable clinical trial results were reported across the global biopharmaceutical industry, spanning oncology and hematologic malignancies, immune-mediated and inflammatory diseases, metabolic disorders, neurological conditions, rare diseases, and ophthalmology. Antibody-drug conjugates (ADCs), T-cell engagers (TCEs), personalized mRNA cancer vaccines, and multispecific antibodies continued to advance through clinical evaluation, while interim data emerged for several new targets and mechanisms.

• October 22| MSD and Moderna | V940 (personalized mRNA neoantigen therapy) | Phase 3: Significant recurrence-free survival benefit, with a 42% reduction in the risk of recurrence or death

The study enrolled 1,137 patients with completely resected stage IIB–IV melanoma and compared V940 plus pembrolizumab with placebo plus pembrolizumab. The 24-month recurrence-free survival (RFS) rate was 82.2% versus 70.0%, representing a 42% reduction in the risk of recurrence or death (HR=0.58). The risk of distant metastasis or death was reduced by 38% (HR=0.62). Overall survival (OS) data remain immature. These findings provide important Phase 3 randomized, controlled evidence for a personalized mRNA cancer vaccine.

• October 24| AstraZeneca | Durvalumab (anti-PD-L1) plus enfortumab vedotin (Nectin-4 ADC) | Phase 3: Improved EFS and OS, but with more Grade ≥3 adverse events

The study enrolled patients with muscle-invasive bladder cancer who were ineligible for or had declined cisplatin-based chemotherapy. It evaluated perioperative durvalumab plus enfortumab vedotin, a triplet regimen adding tremelimumab, and a control regimen. The 24-month event-free survival (EFS) rate was 63.5% versus 45.1% in the doublet arm (HR=0.51) and 60.1% in the triplet arm (HR=0.61). In the doublet arm, the 24-month OS rate was 78.4% versus 69.4% (HR=0.58). Grade ≥3 adverse events occurred in 71.1%, 79.5%, and 50.2% of patients in the doublet, triplet, and control arms, respectively, highlighting the need to balance perioperative benefit against toxicity.

• October 24| Amgen and AstraZeneca | Tarlatamab (DLL3×CD3 TCE) plus durvalumab (anti-PD-L1) | Phase 3: Median OS of 21.1 months and a 58% reduction in the risk of death

Among patients with extensive-stage small-cell lung cancer whose disease had not progressed following platinum-based chemotherapy and induction treatment with durvalumab, tarlatamab plus durvalumab significantly improved OS compared with durvalumab alone. Median OS was 21.1 months versus 12.7 months, corresponding to a 58% reduction in the risk of death (HR=0.42). The results provide important Phase 3 evidence supporting the evaluation of DLL3-targeted TCE therapy in the first-line maintenance setting. As these findings were reported at a medical meeting, they should not be interpreted as an indication approval.

• October 25 | AstraZeneca | Sonesitatug vedotin (CLDN18.2 ADC) | Phase 3: Significant OS benefit, but PFS did not reach statistical significance in the overall population

In the overall CLDN18.2-positive population treated in the second line or later, median OS was 10.6 months versus 6.4 months (HR=0.58). In the primary endpoint population treated in the third line or later, median OS was 10.0 months versus 5.0 months (HR=0.47). However, in the overall population, progression-free survival (PFS) assessed by blinded independent central review (BICR) was 4.2 months versus 3.8 months (HR=0.77; p=0.053), which did not reach statistical significance. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 36.4% versus 44.8% of patients. The results indicate an OS benefit, but should not be described as success across all co-primary endpoints.

• October 25 | Roche | Divarasib (KRAS G12C inhibitor) | Phase 3: Head-to-head data showed improvements in both OS and PFS versus comparator therapy

The head-to-head comparison evaluated divarasib against sotorasib or adagrasib. Median OS was 17.7 months versus 12.0 months (HR=0.56), median PFS was 9.8 months versus 5.7 months (HR=0.58), and the objective response rate (ORR) was 58% versus 32%. The study met its primary and key secondary endpoints, with no new safety signals observed. These findings provide direct comparative evidence for a next-generation KRAS G12C inhibitor against marketed agents in the same class.

• October 27 | Hansoh Pharma | Risvutatug rezetecan (HS-20093, B7-H3 ADC) | Phase 3: Primary endpoint met, with PFS extended from 1.4 to 5.5 months

The study enrolled 122 patients with relapsed or refractory osteosarcoma whose disease had progressed after at least two prior lines of therapy. BICR-assessed PFS, the primary endpoint, was 5.5 months versus 1.4 months (HR=0.33; p<0.0001), representing a 67% reduction in the risk of disease progression or death. ORR was 15% versus 2%, and the disease control rate was 76% versus 33%. OS data remain immature. Grade ≥3 TRAEs occurred in 93% versus 83% of patients, warranting particular attention to hematologic toxicity. The October presentation provided detailed data following the previously announced positive topline results.

• October 27 | Pfizer | Elranatamab (BCMA×CD3 bispecific antibody) | Phase 3: Primary PFS endpoint met; OS remains immature and infection risk warrants attention

In patients with relapsed or refractory multiple myeloma previously treated with an anti-CD38 therapy and lenalidomide, elranatamab monotherapy met the BICR-assessed primary PFS endpoint. Median PFS had not been reached, and the estimated 18-month PFS rate was 68%; OS data remain immature. Grade ≥3 infections occurred in 27.5% of patients, compared with 18.1% in the control group. The company has released topline results; complete efficacy data and statistical details are expected to be disclosed at a subsequent medical meeting.

• October 8 | argenx | Efgartigimod (FcRn antagonist) | Phase 3: Study terminated early for futility; primary endpoint not met

Following an interim analysis, the independent data monitoring committee recommended stopping the UNITY study for futility, concluding that the trial was unlikely to meet its primary endpoint. The company reported that the safety profile was consistent with the previously established profile, with no new safety signals identified. No quantitative efficacy data were disclosed. The outcome underscores that the efficacy of FcRn inhibitors in other antibody-mediated diseases cannot be directly extrapolated to Sjögren’s disease.

• October 20 | Amgen and AstraZeneca | Tezepelumab (TSLP antibody) | Phase 3: Histologic remission in eosinophilic esophagitis reached 68.9%

In adolescents and adults with eosinophilic esophagitis whose symptoms were inadequately controlled, histologic remission rates at Week 24 were 64.8% with 210 mg and 68.9% with 420 mg, compared with 3.5% with placebo. Both dose groups also showed improvements in dysphagia symptoms, with efficacy maintained through Week 52. Common adverse events included nasopharyngitis, headache, and diarrhea; the overall safety profile was consistent with previous studies. The findings support further evaluation of the TSLP pathway in eosinophilic esophagitis.

• October 28 | Eli Lilly | Retatrutide (GLP-1/GIP/glucagon triple receptor agonist) | Phase 3: HbA1c reduced by 2.2 percentage points, with body-weight reductions of up to 20.9%

The study compared retatrutide at 9 mg and 12 mg with semaglutide at 2 mg in adults with type 2 diabetes inadequately controlled with metformin, with or without an SGLT2 inhibitor. At Week 80, mean HbA1c decreased by 2.2 percentage points in both retatrutide groups and by 1.8 percentage points with semaglutide. Body weight decreased by 19.5%, 20.9%, and 9.4%, respectively. Discontinuation due to adverse events occurred in 4.8%, 7.9%, and 2.7% of patients, respectively; gastrointestinal events were common. These are company-reported topline results, with full data expected at a medical meeting and in a subsequent publication.

• October 7 | Cerevance | Solengepras (GPR6 modulator) | Phase 3: Primary endpoint met, with an additional 0.61-hour reduction in daily OFF time

As an adjunct to standard therapies such as levodopa, solengepras reduced daily OFF time in patients with Parkinson’s disease by an additional 0.61 hours versus placebo at Week 12 (p=0.035). ON time without troublesome dyskinesia increased by 0.60 hours (p=0.0468), while some measures of daytime sleepiness and quality of life also showed improvement. The company reported that the treatment was generally well tolerated. By targeting GPR6, a non-dopaminergic receptor, the program explores an alternative therapeutic approach to Parkinson’s disease and provides clinical validation beyond the conventional dopamine pathway.

• October 19 | Disc Medicine | Bitopertin (GlyT1 inhibitor) | Phase 3: Both co-primary endpoints met, with 12.2 additional hours of pain-free time in sunlight per month

In patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), bitopertin met both co-primary endpoints. Whole-blood metal-free protoporphyrin IX (PPIX) was reduced by 41.4% versus placebo (p<0.0001), and average monthly pain-free time in sunlight increased by 12.2 hours at Month 6 (p=0.0010). The most common adverse event was dizziness, reported in approximately 50% of patients; events were mostly mild to moderate and transient. No treatment-emergent adverse events above Grade 3 were reported. The company plans to resubmit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2026.

• October 10 | MSD | Remigromig (Wnt-pathway trispecific antibody agonist) | Phase 2b/3: Noninferiority achieved, but superiority not demonstrated; ocular safety requires attention

In patients with diabetic macular edema, the mean improvement from baseline in best-corrected visual acuity (BCVA) at Week 52 was 9.1 letters with the 0.5 mg dose and 8.7 letters with the 0.8 mg dose, compared with 11.8 letters with ranibizumab. Both dose groups met the prespecified noninferiority criterion but did not demonstrate superiority. Adverse events associated with proliferative diabetic retinopathy occurred in 6.7% and 6.1% of patients in the two dose groups, respectively, higher than the 0.9% reported with ranibizumab. Discontinuation due to adverse events was also more frequent. The findings support the potential of Wnt-pathway modulation, but ocular safety warrants further assessment.

• October 12 | Beacon Therapeutics | Laru-zova (RPGR gene replacement therapy) | Pivotal VISTA study: Primary endpoint met, with a clear signal of improvement in low-luminance visual acuity

The VISTA study enrolled 85 male patients with X-linked retinitis pigmentosa. At Month 12, the proportion of patients achieving an improvement of at least 15 letters in low-luminance visual acuity (LLVA) was 31.0% in the high-dose group and 24.1% in the low-dose group, compared with 0% in the untreated control group. Both dose groups met the prespecified primary endpoint. The company reported a favorable safety and tolerability profile. These data were presented in detail for the first time at the October American Academy of Ophthalmology (AAO) meeting; positive topline results had previously been announced in September.

Overall, clinical development is moving beyond establishing target validity toward demonstrating clinically meaningful benefits for patients, long-term safety, and treatment convenience. For programs supported only by company topline announcements or conference presentations, full study reports, peer-reviewed publications, and longer follow-up will remain important to assessing their clinical value.